Friday, 29 March 2024


Macrocyclics to design chelating agents for Roche

24 May 2013 | News | By BioSpectrum Bureau

Macrocyclics to collaborate with Roche on molecular innovation for nuclear medicine

Macrocyclics to collaborate with Roche on molecular innovation for nuclear medicine

Singapore: Macrocyclics, an Areva Med company, entered into a new collaborative research agreement with Roche for the continued development of novel chelating agents designed specifically by Macrocyclics for Roche's applications. This will be the second collaboration between the two firms after the successful completion of their first 2012 venture.

The new project will build on the already established expertise related to lead-212 (212Pb) and novel chelate architecture for radioimmunotherapy. The high level of synergy between the two firms is expected to speed up the clinical development process.

Mr Garry Kiefer , CEO, Macrocyclics, said that, "We are privileged to be working with the world leader in oncology and antibody technology and are excited to contribute in the development of powerful new therapies based on lead-212."

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account